What Is New in Narrow-Band Ultraviolet-B Therapy for Vitiligo?

Indian Dermatol Online J

Department of Dermatology, All India Institute of Medical Sciences, New Delhi, India.

Published: January 2019

Vitiligo is an acquired disorder of skin pigmentation that produces significant psychological impact especially in those with skin of color. Narrow-band ultraviolet B (NB-UVB) therapy, which was first used in vitiligo in 1997 by Westerhof and Nieuweboer-Krobotova, has emerged as one of the safest and most effective therapy for this dermatosis. The light source used for NB-UVB phototherapy is the TL-01 lamp, and the most common model of the NB-UVB phototherapy device is the upright in-office booth or chamber which has 24-48 such lamps. In recent years, there have been several advances in the understanding of the mechanism of action of NB-UVB and the use of combination treatments, many of which increase the efficacy of NB-UVB. In 2017, the Vitiligo Working Group made vital recommendations on the dosage, frequency, and safety of NB-UVB in vitiligo. Furthermore, home phototherapy devices are gaining popularity as they lead to an improved patient compliance. There is still need for large multicenter randomized controlled trials to assess benefits of home phototherapy in vitiligo and studies investigating additional benefits of phototherapy following surgical therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536079PMC
http://dx.doi.org/10.4103/idoj.IDOJ_310_18DOI Listing

Publication Analysis

Top Keywords

nb-uvb phototherapy
8
benefits phototherapy
8
nb-uvb
6
vitiligo
5
phototherapy
5
narrow-band ultraviolet-b
4
therapy
4
ultraviolet-b therapy
4
therapy vitiligo?
4
vitiligo? vitiligo
4

Similar Publications

Vitiligo is a chronic depigmenting condition that causes amelanotic macules and patches on the skin. Despite various treatment options, treating vitiligo is a challenge. This study aimed to evaluate the combination of laser CO fractional and narrow-band ultraviolet B (NB-UVB) versus NB-UVB monotherapy in vitiligo patients.

View Article and Find Full Text PDF

New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination.

SAGE Open Med Case Rep

December 2024

Department of Dermatology, College of Medicine, University of Saskatchewan, Regina, SK, Canada.

We report a 56-year-old male who developed cutaneous lichen planus (LP) following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination. Multiple topical and systemic therapies were tried with limited success; however, partial improvement was observed with narrow-band UVB (NB-UVB) phototherapy. This report adds to the growing evidence of new-onset LP following COVID-19 vaccination and underscores the need for careful reporting, monitoring, and management of vaccine-related adverse effects.

View Article and Find Full Text PDF

Chronic spontaneous urticaria (CSU) is defined as the occurrence of hives, angioedema, or both, lasting for more than 6 weeks. The treatment is based on the use of antihistamines, omalizumab, and/or cyclosporine following a stepwise algorithm recommended by international guidelines with a high level of evidence. Nevertheless, management can be challenging as some patients do not respond to the suggested drugs or have difficulties accessing them for various reasons.

View Article and Find Full Text PDF

Introduction: This study addresses the gap in research comparing the effectiveness between home and in-office narrowband ultraviolet B (NB-UVB) phototherapy for the treatment of mycosis fungoides (MF). Elderly and disabled patients with this condition disproportionally lack access to home units due to insurance denial.

Materials And Methods: A retrospective review included patients diagnosed with MF or Sezary syndrome who underwent either in-office or home UVB between 2016 and 2023.

View Article and Find Full Text PDF

A Systematic Review of Case Series and Clinical Trials Investigating Regenerative Medicine for the Treatment of Vitiligo.

J Cosmet Dermatol

November 2024

Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.

Aims And Objectives: The aim of this study is to examine the efficacy and safety of various regenerative medicine treatments, such as cell therapy, platelet-rich plasma (PRP), plasma-poor platelet (PPP), plasma-rich fibrin (PRF), mesenchymal stem cells, stromal vascular fraction (SVF), exosomes, adipose-derived stem cells (ADSC), and stem cell-conditioned media (SC-CM), for treating vitiligo.

Method: We conducted a thorough search of major databases such as PubMed, Scopus, and Web of Science, and selected 48 articles based on specific criteria. We used EndNote X8 and Google Sheets to review and extract data from the articles.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!